# Ombre

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ombre

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.ombrelab.com/
- Total disclosed funding: $4M
- Latest round: Seed (Feb 15, 2022)
- Investors on record: 3

## About

Founded in 2016 and based in California, US, Thryve, Inc. trading under the name Ombre, operates as a developer of monthly subscription microbiotics testing solutions that enable users to receive personal insights and health recommendations based on their results. In August 2024, Thryve, Inc. raised EUR 4 million in Series A funding led by Capricorn Partners, with participation from IBB Ventures, CRB Inverbio, and CARMA FUND Management.

Ombre provides a digital solution for gut health through at-home microbiome testing, personalized microbiome reports, and targeted probiotic supplements. The microbiome test kit allows users to collect a sample at home, which is analyzed using DNA sequencing to detect bacterial strains in the gut. Based on this analysis, Ombre provides personalized food recommendations and tailored probiotic formulations to promote digestive health. The entire process is supported by a proprietary bioinformatics pipeline that processes data and generates customized wellness suggestions. 

The company intends to use the August 2024 funding to expand its market reach globally.

## Funding rounds

- Seed, Feb 15, 2022, $4M — Relevance Ventures
- Seed, Feb 17, 2017 — Plug and Play, PivotNorth Capital

## Investors

- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- PivotNorth Capital (https://capitalatlas.ai/funds/pivotnorth-capital) — Seed
- Relevance Ventures (https://capitalatlas.ai/funds/relevance-ventures) — Seed